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Abstract
Liver-directed gene transfer is being investigated for the treatment of systemic or liver-specific diseases. Recombinant
vectors based on adeno-associated virus serotype 8 (AAV2/8) efficiently transduce liver cells allowing long term transgene
expression after a single administration in animal models and in patients.
We evaluated the impact on AAV2/8-mediated rat liver transduction of the following variables: i) age at vector
administration, ii) presence of lysosomal storage in liver cells, and iii) regulatory elements included in the transgene
expression cassette. We found that systemic administration of AAV2/8 to newborn rats results in vector genome dilution
and reduced transduction efficacy when compared to adult injected animals, presumably due to hepatocyte proliferation.
Accumulation of glycosaminoglycans in lysosomes does not impact on levels and distribution of AAV2/8-mediated liver
transduction. Transgene expression occurs in hepatocytes but not in Kupffer or liver endothelial cells when the liver-specific
thyroxine-binding-globulin promoter is used. However, extra-hepatic transduction is observed in the spleen and kidney of
animals injected at birth. The use of target sequences for the hematopoietic-specific microRNA miR142-3p does not
improve liver transduction efficacy neither reduce immune responses to the lysosomal enzyme arylsulfatase B. The inclusion
of a variant of the Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE-m) decreases AAV2/8-mediated
liver transduction levels.
As AAV2/8-mediated liver gene transfer is entering in the clinical arena, these data will provide relevant information to
the design of efficient AAV2/8-based therapeutic strategies.
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Introduction
The liver is the largest organ in the body performing essential
functions in metabolism, detoxification, and production of plasma
proteins [1]. The liver consists of several cell types classified into
hepatocytes (liver parenchymal cells) that constitute about 80% of
liver cells [2] and non-parenchymal cells represented by
endothelial cells, Kupffer cells (resident liver macrophages), fat-
storing cells (stellate cells or Ito cells), and pit cells (natural killer
cells). Kupffer and endothelial cells form the hepatic reticulo-
endothelial system [3] and constitute the majority of liver non-
parenchymal cell types [2]. Given its central role in maintaining
homeostasis and regulating metabolism, and the high accessibility
of hepatocytes via the bloodstream through a fenestrated
epithelium, the liver has been widely utilized for the expression
of therapeutic transgenes via somatic gene transfer [4,5]. This
approach has been used to treat several inherited and acquired
disease models, either affecting the liver itself or requiring systemic
delivery of a therapeutic protein, such as hemophilia, lysosomal
storage disorders, and others [4,5].
Vectors based on the adeno-associated virus serotype 8 (AAV2/
8) hold promise for in vivo liver directed gene transfer [4,5].
Systemic administration of AAV2/8 results in long-term, robust
transgene expression with minimal toxicity and immune responses
in several animal models [4,5]. In addition, preliminary results
from an ongoing clinical trial using AAV2/8 in hemophilia B
patients suggest that systemic AAV2/8 administration is safe and
efficient in humans [6,7]. The AAV vector genome persists mainly
as an episome in transduced hepatocytes with only a small
percentage being integrated in the host cell genome [5,8,9]. While
this is associated with a low risk of insertional mutagenesis, it may
represent a limitation for the transduction of actively replicating
cells as in the case of newborn tissues [4].
Moreover, liver-directed gene delivery has been reported to
induce transgene product-specific immune tolerance [1]. This is
related to the unique cellular environment of the liver, which is
physiologically involved in the appropriate recognition of self
versus non-self molecules and pathogens [10,11]. Reduced or
absent activation of the immune system after vector administration
represents an advantage for the induction of transgene-specific
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to their inefficiency in infecting dendritic cells (DC) or macro-
phages, favours tolerance induction [1]. Despite this, examples of
transgene-directed immune responses following liver gene delivery
have been reported [4,5,12–15]. The tolerance obtained after liver
gene delivery requires optimization of gene transfer strategies to
eliminate transgene expression in antigen presenting cells (APC)
while restricting high levels of therapeutic expression to hepato-
cytes [1].
The choice of regulatory elements to be included in the
transgene expression cassette has a direct impact on the levels and
cellular restriction of gene expression. This is crucial to improve
both therapeutic efficacy and safety, and to avoid the development
of transgene-directed immune responses in liver gene transfer
protocols. Hepatocyte-specific promoters, such as the thyroxine-
binding-globulin promoter (also called liver-specific, TBG or LSP
[16–25]), are often used to obtain liver-restricted transgene
expression. In addition, the inclusion of microRNA (miRNA)
target sequences in the vector expression cassette can help to
eliminate off-target transgene expression from transduced cells
that express the corresponding miRNA [26]. Moreover transgene
expression levels can be improved by the inclusion, in the
transgene expression cassette, of post-trascriptional regulatory
elements such as the Woodchuck hepatitis virus (WHV) post-
transcriptional regulatory element (WPRE, [27]), able to increase
transcript levels and/or stability.
Equally important is the timing of vector administration, as well
as the pathological conditions, that account for alterations of the
microenvironment and cell function of the liver, which could affect
the efficacy and safety of liver gene transfer [4,28].
Here we investigated the impact of the following factors on the
efficacy of AAV2/8-mediated liver gene transfer in rats,
commonly used as animal models for the development of gene
therapy strategies: i) age at vector administration, ii) presence of
lysosomal storage in liver cells, and iii) regulatory elements
included in the transgene expression cassette.
Results
AAV2/8 systemic delivery in newborn rats is associated
with vector dilution and low transduction levels
To assess the impact of rat hepatocyte proliferation on AAV2/
8-mediated liver transduction, we injected rats systemically with
AAV2/8 vectors encoding the enhanced Green Fluorescent
Protein (eGFP) transgene under the control of the liver-specific
TBG promoter (AAV2/8-TBG-eGFP) either at postnatal day (P) 4
or at P30, assuming that the rate of hepatocyte proliferation is
reduced at P30 [29]. Livers from animals administered with AAV
were collected at P90 and levels of transgene expression were
assessed by both analysis of eGFP-positive cells on cryo-sections
(Fig. 1A and Fig. S1A) and anti-eGFP Western blot (Fig. 1B, Fig.
S1B and Fig. S2A). We observed a higher number of eGFP-
expressing cells (Fig. 1A, right panels and Fig. S1A) and a stronger
(but not significantly different) intensity of eGFP bands (Fig. 1B,
P90 white and grey bars, Fig. S1B and Fig. S2A) in livers from
animals injected at P30 compared to those injected at P4.
Concordantly, the number of AAV genome copies/molecule of
diploid genome (gc/mdg) was significantly higher in livers from
animals injected at P30 than in those injected at P4 (Fig. 1C, P90
white and grey bars).
To confirm that the reduced amount of vector genomes and the
lower transgene expression levels observed in livers of rats injected
at P4, as opposed to those injected at P30, were due to the
proliferation-related dilution of episomal AAV vector genomes, we
injected rats at P4 with AAV2/8-TBG-eGFP and collected
livers at P15, P30 and P90. We observed the highest number of
eGFP-positive cells (Fig. 1A), highest eGFP expression levels
(Fig. 1B and Fig. S2B) and vector gc/mdg (Fig. 1C) in livers
collected at P15. These were reduced in animals sacrificed at
later time points with the strongest reduction observed between
P15 and P30. In addition, the eGFP-positive cells in livers
collected at P90 appeared in clusters when rats were injected
at P4 but not at P30 (data not shown), possibly representing clones
from a single cell containing integrated vector genomes, as
previously described in mice injected at birth with AAV2/8 [30].
Thus, as previously reported [9,30,31], hepatocyte prolife-
ration results in dilution of AAV vector genomes in transduced
cells and reduced efficacy of long-term liver transduction in
newborn rats.
To test if AAV vector genome dilution occurs in liver of adult
animals, we injected rats with AAV2/8-TBG-eGFP at P30 and
collected their livers at P41 and at P90. Western blot analysis
showed in some but not all the livers collected at P41 slightly
higher levels of eGFP expression than at P90 (Fig. S2C). However
the quantification of the corresponding eGFP band intensity did
not evidence statistically significant differences (Fig. 1B, white and
dark grey bars). Thus, although we can’t exclude that in some
animals vector dilution occurs in liver of rats injected at P30,
overall this was not significant. Interestingly, the amount of liver
vector genomes at P41 is significantly higher than at P90 (Fig. 1C,
white and dark grey bars). Since these differences are not reflected
by the transduction levels, we hypothesize that some of the AAV
genomes in liver at P41 are single-stranded and thus transcrip-
tionally inactive, and are then lost at P90.
Overall, liver transgene expression levels seem higher 11 days
after vector injection at P4 (Fig. S2B, P15) than at P30 (Fig. S2C,
P41) suggesting that AAV2/8-mediated liver transduction is more
efficient in newborn than in adult rat liver.
Lysosomal storage does not reduce the efficacy of AAV2/
8-mediated hepatocyte transduction
Lysosomal storage disorders (LSD) are excellent candidate
diseases for gene therapy because: i) lysosomal enzymes are
secreted by producing cells and uptaken by deficient cells [32], ii)
relatively low levels (5–10% of normal) of lysosomal enzymes are
expected to significantly reduce morbidity [33], and iii) enzyme
replacement therapy that exists for several lysosomal enzymes
requires costly, life-lasting infusions that do not completely resolve
LSD. We have recently described the efficacy of AAV2/8-
mediated liver gene transfer in animal models of mucopolysac-
charidosis VI (MPS VI), an LSD characterized by glycosamino-
glycan (GAG) storage in various tissues including liver (Fig. 2A)
due to arylsulfatase B (ARSB) deficiency [14,15,34].
Here we set up to test if GAG storage has an impact on
AAV2/8-mediated liver transduction using a rat model of
MPS VI [14]. Normal (NR) and MPS VI affected (AF) rats were
injected at P30 with AAV2/8-TBG-eGFP vectors. Livers were
collected at P90 and the efficiency of AAV2/8-mediated
transduction was assessed. We observed a similar number of
eGFP-positive liver cells (Fig. 2B) and a comparable intensity of
eGFP bands by Western blot on liver lysates from NR and AF rats
injected with AAV2/8-TBG-eGFP (Fig. 2C and Fig. S2D). In
addition, we did not detect any significant difference in the
amount of liver AAV vector genomes between the two animal
groups (Fig. 2D). This suggests that lysosomal storage does not
significantly impact on AAV2/8-mediated liver transduction in
MPS VI rats.
AAV8-Mediated Liver Transduction in Rats
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The TBG or Liver-Specific (LSP) synthetic promoter is often
used in the context of liver gene transfer [14–25,34]. To assess
whether TBG drives transgene expression specifically to hepato-
cytes after systemic administration of AAV2/8, we injected rats at
P4 or at P30 with 4610e13 gc/kg of AAV2/8-TBG-eGFP.
Tissues from injected and uninjected animals were collected at the
same time points reported in the previous section and vector
biodistribution as well as eGFP expression levels were analyzed in
the liver, spleen, kidney, muscle, heart and gonads. Liver cryo-
sections were stained with anti-albumin to identify hepatocytes
(Fig. 3A, left panels, red signal), anti-CD163 to mark Kupffer cells
(Fig. 3A, middle panels, red signal) or anti-CD-31 to label
Figure 1. AAV2/8 administration to newborn rats is associated with vector genome dilution. A) Wild-type rats were injected at either
postnatal day 4 (P4, upper pictures), or at P30 (lower picture) with 4610e13 gc/kg of AAV2/8-TBG-eGFP. Animals injected at P4 were sacrificed at P15,
P30 or P90, while those injected at P30 were analysed at P90. EGFP expression was confirmed under a fluorescence microscope on sections from
transduced livers. Representative pictures from animals in each group are shown. Magnification: 206. B) The eGFP expression levels were analyzed by
Western blot of liver lysates from AAV-injected rats. The intensity of eGFP band was quantified, normalized on the corresponding tubulin band and
expressed as fold of increase in each animal group compared to rats injected at P4 and sacrificed at P90. Results are reported as mean 6 SE. The
number of rats analyzed in each group is reported in each bar. *: p,0.05. The fold of increase of eGFP expression in livers from rats injected at P30
(white bar) compared to rats injected at P4 (light grey bar) and collected at P90 is 2.2560.95. C) AAV vector genome copies per molecule of diploid
genome (gc/mdg) were measured by Real-time PCR in Hirt DNA extracted from injected rats. Results are reported as mean 6 SE. The number of rats
analyzed in each group and statistical significance is reported as before.
doi:10.1371/journal.pone.0033286.g001
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confocal microscopy to co-localize eGFP with one of the three
markers (Fig. 3A). eGFP co-localized with albumin but not with
CD163 or CD-31, independently of the age at vector administra-
tion (Fig. 3A) suggesting that AAV2/8-TBG vector administration
results in hepatocyte-specific transduction in the rat liver. Similar
results were obtained in MPS VI rats injected at P30 with AAV2/
8-TBG-eGFP vectors (data not shown), suggesting that lysosomal
storage does not alter the pattern of AAV2/8-TBG-mediated liver
transduction. The low levels of endothelial cell transduction
mediated by AAV2/8-TBG were additionally observed in human
cell lines. Human hepatoma (HepG2) and human umbilical vein
endothelial (HUVEC) cells were infected with 1610e5 (data not
shown) or 5610e5 gc/cell of AAV2/8-TBG-eGFP vectors or
vectors encoding eGFP under the control of the ubiquitous
chicken beta-actin promoter (AAV2/8-CBA-eGFP). The percent-
age of eGFP-expressing cells was determined by FACS analysis.
While both HepG2 and HUVEC cells were transduced efficiently
when using AAV2/8-CBA-eGFP, HepG2 but not HUVEC cells
were transduced by AAV2/8-TBG-eGFP (Fig. S3).
AAV vector genomes were detected by Real-time PCR in the
spleen, kidney, muscle, heart and gonads of rats injected either at
P4 (collected at P15, P30 and P90) or at P30 (collected at P90)
(Fig. 3B). Western blot analysis with anti-eGFP antibodies of
lysates from the same tissues did not show detectable eGFP in the
muscle, heart and gonads of treated rats, independently of the age
at vector administration (Fig. 3C, lower panels and data not
shown). However, low levels of eGFP protein (Fig. 3C, left panels)
and transcript (Fig. S4) were detected in the spleen and kidney
from rats injected at P4, suggesting that TBG-driven expression is
not restricted to hepatocytes when AAV2/8 is administered
systemically to newborn rats. Interestingly, while TBG-driven
eGFP expression was detected in the spleen until P90 after vector
administration (the last time point of the study), ectopic eGFP
expression in the kidney was undetectable after P15 (data not
shown). Inclusion of target sequences for the hematopoietic
lineage-specific miRNA miR142-3p (miR142-T) in the 39UTR
of the transgene expression cassette has been reported to de-target
transgene expression from hematopoietic cells in the spleen [35].
To test if this strategy can be exploited to inhibit ectopic transgene
expression in the spleen of rats injected at P4 with AAV2/8-TBG
vectors, we generated AAV2/8-TBG-eGFP vectors carrying four
copies of the miR142-T (miR142-Tx4) immediately downstream
of the eGFP coding sequence (see Materials and Methods). Wild-
type rats were injected at P4 with 4610e13 gc/kg of either AAV2/
8-TBG-eGFP or AAV2/8-TBG-eGFP-miR142-Tx4. Eleven days
after vector delivery, Western blot analysis of eGFP expression
showed transgene expression in liver but not spleen of rats
receiving AAV2/8-TBG-eGFP-miR142-Tx4 (Fig. S2F) confirm-
ing that the inclusion of miR142-T prevents transgene expression
in this ectopic site. We have also observed that liver eGFP
expression was lower in rats receiving vectors containing miR142-
T compared to those injected with AAV2/8-TBG-eGFP (Fig. S2F
and S2B respectively). We speculate that the addition of the
miR142-T sequence to the eGFP transcript may reduce its
stability.
Inclusion of the WPRE sequence in the 39 UTR of the
transgene expression cassette has been reported to increase
expression levels in the context of various viral vectors and cell
types [36–51]. However, concerns have been raised regarding the
inclusion of WPRE in viral vectors because its sequence overlaps
with that of the WHV X protein (WHX), a transcriptional
activator implicated in the development of liver tumors [52,53].
To avoid expression of WHX-derived polypeptides, a version of
WPRE mutated in both the WHX promoter and the translation
start sequence has been generated which has an efficacy in
transgene expression enhancement similar to that of the wild-type
WPRE sequence [51,54]. We tested the impact of this mutant
WPRE variant (WPRE-m, bp 1094–1636, GenBank J04514 and
[51]), on transgene expression levels both in the human HepG2
hepatoma cell line and in the rat liver.
Figure 2. Lysosomal storage does not impact on AAV2/8-
mediated liver transduction. A) Alcyan blue staining performed on
liver sections from wild-type (NR) and MPS VI (AF) rats injected with
AAV2/8-TBG-eGFP shows GAG storage (blue staining) in AF but not NR
rats. Representative pictures from animals in each group are shown.
Magnification: 206. B) NR and AF rats were injected at P30 with
4610e13 gc/kg of AAV2/8-TBG-eGFP vectors. Animals were sacrificed at
P90 and eGFP expression levels were assessed under a fluorescence
microscope on sections from transduced livers. Representative pictures
from animals in each group are shown. Magnification: 206. C) eGFP
expression levels were assessed by Western blot analysis of liver lysates
from the same animals as in panel B. The intensity of eGFP bands was
measured and normalized to that of the corresponding tubulin band.
Results are reported as mean 6 SE. The number of animals analyzed in
each group is reported in each bar. D) AAV vector genome copies/
molecule of diploid genome (gc/mdg) were measured by Real-time PCR
in livers of rats injected with AAV2/8. Results are reported as mean 6
SE. The number of animals analyzed is reported as before.
doi:10.1371/journal.pone.0033286.g002
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33286Figure 3. TBG-driven transgene expression in tissues of rats injected with AAV2/8. A) Hepatocyte-restricted eGFP expression in the liver of
rats injected with AAV2/8-TBG-eGFP. Wild-type rats were injected at P4 (upper pictures), or at P30 (lower pictures) with 4610e13 gc/kg of AAV2/8-
TBG-eGFP vectors. Animals were sacrificed at P15 (those injected at P4) or at P90 (those injected at P30). The identity of eGFP expressing cells in the
liver from injected rats was confirmed by confocal microscopy analysis on sections after immuno-fluorescence with anti-albumin (left panels), anti-
CD163 (middle panels, white arrows) or anti CD-31 (right panels, white arrows) antibodies. Representative pictures from rats in each group are shown.
Magnification: 636. B, C) Analysis of vector bio-distribution and eGFP expression in tissues from rats injected with AAV2/8-TBG-eGFP. B) AAV vector
genome copies/molecule of diploid genome (gc/mdg) were measured in tissues (reported under each bar) from rats injected at P4 (left, for spleen,
kidney, muscle, heart and gonads data are pooled from tissues harvested at P15, P30 and P90) or at P30 (right, all tissues harvested at P90) by Real-
time PCR. Results are reported as mean 6 SE. The number of animals analyzed in each group is reported in the corresponding bar. C) eGFP expression
was assessed by Western blot analysis on the spleen (70 mg of proteins) , kidney (70 mg of proteins) and heart (150 mg of proteins). Representative
animals from each group are shown. 2: tissues from uninjected rats; +: liver lysate from a rat injected at P4 with AAV2/8-TBG-eGFP and collected at
P15 used as eGFP-positive control (10 ug of proteins).
doi:10.1371/journal.pone.0033286.g003
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encoding eGFP or feline ARSB (fARSB) under the control of
the TBG promoter, containing or not the WPRE-m element
(pAAV-TBG-eGFP, pAAV-TBG-eGFP-WPRE-m, pAAV-TBG-
fARSB, pAAV-TBG-fARSB-WPRE-m). Similar levels of eGFP
[eGFP (OD): 27460.4 for pAAV-TBG-eGFP and 301618 for
pAAV-TBG-eGFP-WPRE-m transfected cells] or normalized
ARSB activity [ARSB(nmol/mg/h)/eGFP(OD): 0.3660.04 for
pAAV-TBG-fARSB and 0.3760.05 for pAAV-TBG-fARSB-
WPRE-m transfected cells] were measured independently of the
WPRE-m inclusion. We then injected rats at P30 with AAV2/8-
TBG-eGFP vectors including or not the WPRE-m variant and
assessed transgene expression levels in livers collected at P90. We
analyzed both the presence of eGFP positive cells on cryo-sections
by fluorescence microscopy and eGFP levels of expression in liver
lysates by Western blot with anti-eGFP antibodies (Fig. 4A and B,
Fig. S2E and Fig. S5A). Despite the presence of similar amounts of
AAV vector genomes (Fig. 4C and Fig S5B), the levels of eGFP
expression appeared lower in livers receiving the vectors with than
without WPRE-m (Fig. 4A and B, Fig. S2E and Fig. S5A). To
exclude that the differences observed in eGFP expression levels
were due to the quality of viral vector preparations, three
independent experiments using 3 different preps of vector for
each construct were performed and showed similar results (Fig. 4A
and B, Fig. S2E and Fig. S5A).
Neutralizing humoral immune responses to a secreted transgene
product has often limited the efficacy of liver-directed gene
transfer [14,15,26,55,56]. In some instances, this has been solved
using liver-specific promoters [1] presumably by avoiding ectopic
transgene expression in APC. In addition, age at vector
administration has been shown to impact on levels of immune
reponses to the transgene product [57]. Indeed, as we have
previously reported [15], serum ARSB activity measured over time
in null MPS VI rats receiving AAV2/8-TBG vectors encoding
human ARSB (hARSB) at P4 were higher than those measured in
rats injected with the same vectors at P30 (Fig. 5B and 5C). This
correlates with the lower levels of anti-ARSB antibodies developed
in rats injected as newborn compared to those injected at P30
(Fig. 5D and E and [15]). The extent of the humoral immune
response may thus explain the lower circulating ARSB activity
detected in animals treated at P30 compared to those injected at
P4.
The development of neutralizing antibodies to ARSB in null
MPS VI rats was not completely prevented neither by using a
liver-specific promoter nor by administering vectors at P4 (Fig. 5D
and E and [15]). Only when immuno-suppressant drugs were co-
administered with AAV vectors, the production of systemic
antibodies to ARSB was inhibited and higher levels of circulating
ARSB were obtained [15]. More recently, inclusion of miR142-T
sequences in the transgene expression cassette has been used to
avoid off-target transgene expression in APC and prevent
transgene-directed immune responses in the context of liver-
directed gene transfer [35]. To avoid the use of immuno-
suppressant drugs, we tested whether inhibition of ectopic
transgene expression through the inclusion of miR142-Tx4 in
our vectors could prevent the development of transgene-directed
immune responses to ARSB in MPS VI rats. MPS VI rats were
injected either at P4 or at P30 with 4610e13 gc/kg of either
AAV2/8-TBG-hARSB or AAV2/8-TBG-hARSB-miR142-Tx4.
Animals were followed-up for 6 months after vector delivery and
were then sacrificed for analysis of ARSB expression in liver. The
levels of liver ARSB activity were similarly increased in rats
receiving AAV2/8 vectors at P4 compared to AF controls,
independently of the inclusion of the miR142-Tx4 element
(Fig. 5A). This is different from what we observed when the
miR142-Tx4 sequence was included in the eGFP encoding
vectors, resulting in reduced levels of liver transgene expression
(Fig. S2). However this is not surprising since the miR142-Tx4
sequence may negatively impact on the stability of transcripts
deriving from the eGFP but not from the ARSB expression
cassettes used in this study. Monthly serum ARSB activity was very
low in rats treated as newborns, independently of the presence of
miR142-T sites (Fig. 5B). Indeed, serum anti-ARSB antibodies
could be measured in rats receiving the miR142-3p-regulated
vector, even though at slightly lower levels than those injected with
AAV2/8-TBG-hARSB vectors (Fig. 5D). Similar data were
obtained in rats injected at P30 (Fig. 5C and E), suggesting that
the inclusion of binding sites for miR142-3p in AAV2/8-TBG-
hARSB vectors does not avert the development of anti-ARSB
humoral immune responses.
Discussion
Given the growing interest in AAV2/8-mediated liver gene
transfer, here we evaluated in rats the impact of variables
commonly affecting the efficacy and specificity of hepatocyte
transduction.
For several severe and progressive diseases, early treatment is
required to achieve therapeutic efficacy. We previously reported
peak-and-drop kinetics of transgene expression after AAV2/8-
mediated liver neonatal gene transfer in MPS VI rats and cats
[15,34]. The results described here suggest that AAV vector
dilution occurs in the first weeks after gene delivery in newborn
rats and is associated with strong reduction of transgene expression
levels, as previously reported [4,30,31]. This is expected given the
high rate of hepatocyte proliferation in the neonatal period [29]
and the episomal status of recombinant vector genomes in cells
transduced with AAV [8,9]. However additional factors, i.e.
cytotoxic immune responses to AAV-transduced cells, should not
be completely ruled out. Differently from newborn liver, murine
adult hepatocytes are replaced very slowly, approximately once
every 180–400 days [58]. Indeed, delivery to adult murine
hepatocytes allows to obtain robust long-term transgene expres-
sion [4,9]. Consistent with this, we observed higher transgene
expression levels in the livers of animals injected at P30 than those
treated at P4. Since the rat liver mass increases for at least 100
days after birth [29], we tested if AAV vector dilution could also
occur in the liver of rats injected at P30. Although we observed a
reduction in the amount of rat liver vector genomes over time after
AAV delivery at P30, we could not detect significant differences in
transgene expression levels. A possible explanation for this, could
be that single-stranded, transcriptionally inactive AAV genomes
are lost between P41 and P90.
Liver gene transfer has been used to create a depot organ for
long-term release of lysosomal enzymes as a potential therapeutic
strategy for LSD [4,5]. Lysosomal storage causes tissue inflam-
mation, alteration of cellular degradation pathways such as
autophagy and increased rate of apoptosis [59–61]. We show that
this does not impact either on the levels or on the pattern of cell
transduction within the liver parenchyma of AAV2/8 in MPS VI
rats up to day 90, the last time point of the analysis. However, we
can not exclude that loss of AAV genomes may occur later in the
MPS VI rat liver as result of the presence of activated
macrophages and increased apoptosis as we have previously
reported [14,61].
Regulation of gene expression in space and levels is required for
safe and efficient gene therapy. Liver-specific promoters are often
used to restrict viral vector-mediated expression to hepatocytes. As
AAV8-Mediated Liver Transduction in Rats
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synthetic and native hepatocyte-specific promoters [35,62], we
tested if this is also the case with the widely used TBG promoter.
Although we found that AAV2/8-TBG-mediated transduction is
restricted to hepatocytes in both wild-type and MPS VI liver, we
observed detectable eGFP expression in the spleen and kidney of
wild-type rats injected systemically with AAV2/8-TBG-eGFP at
P4, suggesting that the TBG promoter is not hepatocyte-specific,
at least in newborn rats. This partially agrees with data reported
from Bell et al. and Wang et al., showing that low levels of eGFP
mRNA are detected in the spleen of dogs [25] and non-human
primates [22] injected sistemically with AAV2/8-TBG-eGFP.
However, we can not exclude that the eGFP expression we
observed in non-hepatic rat tissues may derive from the promoter
activity associated with the AAV inverted terminal repeats (ITR)
[63].
Interestingly, AAV vector genomes were higher in the spleen
from rats injected at P30 compared to those injected at P4; thus,
proliferation-related dilution of AAV vector genomes may occur in
newborn spleen as observed for the liver. Alternatively, efficiency
of adult and newborn spleen cells transduction after systemic
AAV2/8 administration might be different. In addition, it is
possible that different cell types are transduced in newborn and
adult spleen after systemic AAV2/8-injection, and this could
Figure 4. Inclusion of the WPRE-m variant is associated with decreased hepatocyte transduction levels in rats. A) Rats were injected at
postnatal day (P)30 with 4610e13 gc/kg of AAV2/8-TBG-eGFP or AAV2/8-TBG-eGFP-WPRE-m vectors. Animals were sacrificed at P90 and eGFP-
positive cells were visualized on liver sections under a fluorescence microscope. Representative pictures from animals in each group are shown.
Magnification 206. B) eGFP expression levels were assessed by Western blot analysis on liver lysates from the same animals as in panel A. The
intensity of eGFP bands was measured and normalized on that of the corresponding tubulin band. Results are reported as mean 6 SE of three
independent experiments. The number of animals analyzed in each group is reported inside each bar. *: p,0.05. C) AAV vector genome copies/
molecule of diploid genome (gc/mdg) were measured by Real-time PCR in livers of rats injected with AAV. Results are reported as mean 6 SE of three
independent experiments. The number of animals analyzed in each group is reported inside each corresponding bar. The p-value between the TBG-
eGFP and TBG-eGFP-WPRE-m groups is 0.44.
doi:10.1371/journal.pone.0033286.g004
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33286Figure 5. Inclusion of target sequences for miR142-3p in the AAV vector genome does not reduce immune responses to ARSB in
MPS VI rats injected with AAV2/8-TBG-hARSB. MPS VI rats were injected either at P4 or at P30 with AAV2/8-TBG-hARSB or AAV2/8-TBG-hARSB-
miR142-Tx4 vectors. Animals were followed up for 6 months after vector delivery when they were sacrificed for analysis of tissue ARSB expression. A)
Liver ARSB activity was measured at the time of sacrifice in rats injected at P4 with AAV2/8-TBG-hARSB or AAV2/8-TBG-hARSB-miR142-Tx4. The
number of animals analyzed in each group is reported in each bar. NR: control rats AF: uninjected MPS VI rats. *=p,0.05. The p-value between the
TBG-hARSB and TBG-hARSB-miR142-Tx4 groups is 0.12. B, C) Serum ARSB activity was measured each month in NR and AF rats (light grey horizontal
grids) and in rats injected with either AAV2/8-TBG-hARSB or AAV2/8-TBG-hARSB-miR142-Tx4 vectors at P4 (B) or at P30 (C). Results are reported as
mean 6 SE for each group. D, E) Serum anti-ARSB antibodies were measured by ELISA each month in AF rats injected with either AAV2/8-TBG-hARSB
or AAV2/8-TBG-hARSB-miR142-Tx4 vectors at P4 (D) or at P30 (E). As negative control anti-ARSB antibodies were measured in sera from NR and AF
rats that did not receive AAV vectors (uninjected controls). Results are reported as mean 6 SE for each group.
doi:10.1371/journal.pone.0033286.g005
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from rats injected at P30, despite the high number of gc/mdg. Off-
target transgene expression in splenic APC cells after systemic
injection of lentiviral vectors has been described to induce
transgene-directed immune responses in the context of liver-
directed gene transfer [35]. This was avoided by the inclusion of
target sites for miR142-3p in the transgene expression cassette.
Even though AAV vectors are considered overall inefficient at
APC transduction [1,64], transgene expression in DC or
macrophages has been reported after AAV delivery [65,66]. We
hypothesized that this may contribute to the anti-hARSB immune
responses we observed in MPS VI rats after liver transduction with
AAV2/8-TBG-hARSB [14,15] and that this could be prevented
by the inclusion of the miR142-Tx4 element in the AAV2/8-
TBG-hARSB expression cassette. However, the low ARSB serum
levels and the high anti-ARSB antibody titers we found despite the
use of the miR142-3p target sequence argue against this. This is
not surprising since ARSB, like other lysosomal enzymes, is
secreted from producing cells and can be efficiently uptaken via
the mannose-6-phosphate receptor pathway from non-transduced
cells [32], possibly including APC, thus resulting in immune
system activation independently of APC transduction. In addition,
the inflammatory process, which is associated with storage in MPS
VI liver [14,61] may favour the development of immune responses
against the transgene [28].
The WPRE element has been included in gene therapy vectors
with the goal of increasing transduction levels. However, the
impact of WPRE inclusion on transgene expression is variable and
depends on the context of the promoter [43,67–69], the transgene
[70], the gene transfer vector used [49,54] and target cell type
[42,68,69,71–73]. Notably, in some instances the use of WPRE
has been reported to decrease transgene expression levels [69,72–
75]. Indeed, we found that the inclusion of a WPRE variant
(WPRE-m) either did not increase AAV-mediated transduction
levels in vitro or resulted in reduced transgene expression in rat
liver. Others have described increased transgene expression levels
in murine liver using adenoviral or AAV vectors including WPRE
[42,45,46]. The following differences with our study may be
responsible for this apparent discrepancy: i) the rodent specie used,
as others have used mice and we used rats; ii) the promoter/vector
context which are different from our study; iii) the WPRE
sequence as the WPRE-m we used is partially deleted in the b sub-
element [27]. Indeed, work from Shambach et al. [54] and
Donello et al. [27] has shown that WPRE devoid of the entire b
sub-element has reduced activity in vitro (30 [27] to 75% [54] of
normal). Interestingly, in two independent studies, the use of
WPRE sequences lacking the b subunit has been shown to have
detrimental effect on transgene expression levels in some subsets of
hematopoietic cells [72,73]. Thus it is possible that the WPRE-m
sequence selected in our study is responsible for the observed
detrimental effect on AAV2/8-mediated rat liver transduction.
Since the WPRE-m element selected in this study is shorter than
the WPRE used in studies where increased transgene expression
levels were observed following AAV transduction [37,38,45,47]
the conclusions on the effect of WPRE-m should not be extended
to other WPRE sequences.
In conclusion we show that: i) systemic AAV2/8 administration
to newborn rats is associated with vector dilution and low
transduction levels; ii) the combination of AAV2/8 with the
hepatocyte-specific promoter TBG prevents transgene expression
in liver Kupffer and endothelial cells but not in newborn kidney
and spleen; iii) the inclusion of target sequences for the miR142-3p
in the expression cassette of the lysosomal enzyme ARSB does not
prevent humoral immune responses to the transgene, and iv) the
inclusion of WPRE-m in AAV2/8-TBG vectors is associated with
decreased rat liver transduction levels.
These data will be useful when designing liver gene therapy
strategies based on systemic administration of AAV2/8.
Materials and Methods
Ethics Statement
All studies on rats were conducted in strict accordance with the
institutional guidelines for animal research and with the Guide for
the Care and Use of Laboratory Animals of the National Institutes
of Health. All animal treatments were reviewed and approved by
the Ethics Committee for Animal Experimentation (CESA, ‘‘Carlo
Bo’’ University, Urbino, Italy) on May 17, 2007. All procedures on
rats were then approved by the Italian Ministry of Health (protocol
number: 581/07; approval date Sept. 09, 2007).
All surgery was performed under anesthesia, and all efforts were
made to minimize suffering.
Plasmids and vector production
The TBG synthetic promoter used in this study contains
contains a human thyroid hormone-binding globulin promoter
sequence (GenBank ID: NT011651.17) and two copies of an a1-
microglobulin/bikunin enhancer sequence (GenBank ID:
NT008470.19) [16].
The plasmids pAAV2.1-TBG-fARSB [34] and pAAV2.1-TBG-
fARSB-WPRE-m [34] were used for transfection of HepG2 cells
(ATCC-LGC Standards, Milan, Italy).
AAV vectors were produced by the AAV Vector Core of the
Telethon Institute of Genetics and Medicine (TIGEM, Naples,
Italy) by triple transfection of 293 cells (ATCC-LGC Standards,
Milan, Italy) and purified by CsCl gradients. Physical titers of the
viral preparations (genome copies [gc]/ml) were determined by
Real-time PCR (Applied Biosystems, Foster City, CA, USA) and
dot blot analysis.
The following plasmids were used for the production of the
AAV vectors used in our study:
The pAAV2.1-TBG-eGFP-WPRE-m [15] and pAAV2.1-TBG-
hARSB [15] plasmids were used to produce the corresponding
AAV2/8-TBG-eGFP-WPRE-m and AAV2/8-TBG-hARSB vec-
tors. pAAV2.1-TBG-eGFP-WPRE-m was digested with BamHI
and BglII (Roche, Basel, Switzerland) to remove WPRE-m and
was used to produce AAV2/8-TBG-eGFP vectors.
To generate the pAAV2.1-TBG-hARSBmiR142-Tx4 plasmid,
four copies of a sequence perfectly complementary to miR142-3p
[35] (underlined in the primer sequence below) were cloned in the
BglII restriction site between the hARSB stop codon and the
polyA sequence of pAAV2.1-TBG-hARSB. The miR142-Tx4
element was constructed by annealing the following two sets of
oligonucleotides:
59-CTAGATCTTCCATAAAGTAGGAAACACTACACGA-
TTCCATAAAGTAGGAAACACTACAAAGCTT -39;
59- TGTAGTGTTTCCTACTTTATGGAATCGTG-
TAGTGTTTCCTACTTTATGGAAGAT-39 and
59- TCCATAAAGTAGGAAACACTACATCACTCCA-
TAAAGTAGGAAACACTACAAGATC -39;
59- TCGAGATCTTGTAGTGTTTCCTACTTTATG-
GAGTGATGTAGTGTTTCCTACTTTATGGAAAGCTT -
39. The resulting double-stranded fragments (each one containing
two copies of miR142-T) were ligated thanks to the presence of
phosphorylated 59 ends. The obtained fragment (containing four
copies of miR142-T) was subcloned in pBluescript II SK(+)
previously digested with XbaI and XhoI. The recombinant clones
were digested with BglII to release the fragment containing the
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pAAV2.1-TBG-eGFP-miR142-Tx4 plasmids, the eGFP coding
sequence was excised from pAAV2/8-TBG-eGFP by restriction
enzyme digestion with NotI and HindIII (Roche, Basel, Switzer-
land); the resulting eGFP fragment was then cloned in pAAV2.1-
TBG-hARSBmiR142-Tx4 previously digested with NotI and ClaI
to remove the hARSB coding sequence while keeping miR142-
Tx4. To allow the ligation between the ClaI and HindIII non-
compatible protruding ends, fill-in was performed with DNA
Polymerase I, Large (Klenow) Fragment (New England Biolabs,
Ipswich, MA).
Animal procedures and vector administration
Rats from the MPS VI colony [15] mantained at Centre of
Biotechnology, Animal Research Unit, Cardarelli Hospital
(Naples, Italy) were used in this study. Heterozygous (het) animals
were bred to produce normal (NR), het and affected (AF) off-
spring. Genotype analysis was performed by polymerase chain
reaction on genomic DNA as described previously [15] and the
presence of the mutation was confirmed by sequencing (PRIMM,
Naples, Italy).
AAV2/8 vectors were administered to NR and MPS VI rats in
the temporal vein (for P4 injections) or in the femural vein (for P30
injections) at a dose of 4610e13 gc/kg. Animals receiving AAV2/
8-TBG-hARSB or AAV2/8-TBG-hARSB-miR142-Tx4 vectors
received in addition 4610e12 gc/kg of AAV2/8-TBG-eGFP-
WPRE-m to confirm liver transduction. To minimize variability
related to the quality of viral vector preparations, NR rats injected
at P4 for the experiment in Fig. 1 received the same batch of
vector. Similarly, NR and MPS VI rats injected at P30 for
comparison of liver transduction efficacy (Fig. 2) received the same
vector preparation. For comparison of transduction efficacy
between vectors containing or not the WPRE-m, three indepen-
dent groups of rats were injected with three different preparations
of each vector which gave similar results (Fig. 4).
Sera from rats injected with AAV2/8-TBG-hARSB or AAV2/
8-TBG-hARSB-miR142-Tx4 vectors were collected each month
for analysis of ARSB activity and anti-ARSB antibodies.
At the time points reported in the Results section, animals were
sacrificed and tissues were collected for subsequent analysis. For
ARSB activity assays and Western blot analysis, tissues were snap
frozen in dry-ice. For histological analysis, tissues were fixed in 4%
PFA or 10% neutral buffered formalin (Sigma-Aldrich, Milan,
Italy) and embedded in OCT compound (KALTEK, Padova,
Italy). For analysis of GAG storage, tissues were fixed in
methacarn (30% chloroform, 60% methanol, 10% acetic acid)
and embedded in paraffin with standard procedures.
EGFP expression and immuno-fluorescence analysis
For evaluation of eGFP expressing cells, 12 mm sections from
PFA fixed, OCT-embedded livers were analyzed under a
fluorescence microscope. For immuno-fluorescence with anti
Albumin antibodies, 3 mm sections from PFA fixed, OCT-
embedded livers were post-fixed in PFA 4% for 209 at room
temperature (RT), permeabilized with 0.3% Triton in PBS for 109,
blocked in PBS, 0.3% triton, 5% normal rabbit serum for 1 h at
RT and incubated over night with sheep anti-albumin antibodies
(Abcam AB98940, Cambridge, UK, 1:100 dilution) in the same
solution. After washing in PBS, the secondary antibody, diluted
1:1000 in blocking solution, was added (594-AlexaFluor anti-
sheep, Invitrogen Corporation, Carlsbad, CA, USA).
Staining with anti-CD163 antibodies was similarly performed
on 3 mm PFA fixed liver sections blocked O.N. with PBS, 0.1%
triton, 10% FBS, 0.1% BSA, incubated for 2 h at RT with mouse
anti-CD163 antibodies (1:100 dilution in the same solution,
Serotech MCA342r, Oxford, UK) and then with the secondary
antibody (diluted 1:1000, 594-AlexaFluor, anti-mouse, Invitrogen
Corporation, Carlsbad, CA, USA). Immuno-fluorescence with
mouse anti-CD31 antibodies (Serotech MCA1334, Oxford, UK)
was performed on 5 mm frozen sections from OCT-embedded
formalin-fixed livers. Sections were blocked O.N. with PBS, 0.1%
triton, 5% FBS, 1% BSA, incubated for 2 h at RT with mouse
anti-CD31 antibodies (diluted 1:100 in PBS, 0.1% triton, 1% FBS,
1% BSA) and then with the secondary antibody (diluted 1:1000 in
the same solution, 594-AlexaFluor, anti-mouse, Invitrogen Cor-
poration, Carlsbad, CA, USA). Slides were mounted with
vectashield medium (Vectorlabs, Burlingame, CA, USA) and
pictures were taken with a confocal microscope (LSM510, Carl
Zeiss, Milan, Italy).
Western blot analysis
For Western blot analysis, tissues were homogenized in RIPA
buffer (50 mM NaCL, 25 mM TrisHCl pH 8.0, 0.5% NP40,
0.1% SDS, 10 mg/ml leupeptin–aprotinin– pepstatin A) with a
tissue lyser (Qiagen). Protein concentration was determined with
the BCA protein assay reagent (Pierce Chemical Co, Boston, MA,
USA); 50 mg of lysates for the liver, 70 mg for kidney and spleen
and 150 mg for gonads, heart and gastrocnemious were separated
by SDS page on a 14% polyacrylamide gel, transferred to a PVDF
membrane (Roche, Basel, Switzerland) and incubated with anti
eGFP antibodies (Santa Cruz Biotechnology, Santa Cruz, CA,
1:500 dilution). An HRP-labeled anti rabbit antibody (1:1000
dilution) was then used for detection (Amersham Biosciences,
Piscataway, NJ, USA). Filters were then stripped and reprobed
with anti-Tubulin antibodies (Sigma-Aldrich, Milan, Italy, 1:1000
dilution).
Western blot band intensity was quantified with the ImageJ
1.386software (http//rsb.info.nih.gov) and the intensity of eGFP
bands was normalized on the corresponding tubulin band and
used for comparisons.
AAV vector genome distribution
Genomic DNA was extracted from snap frozen tissues after lysis
in a buffer containing 10 mM Tris, 10 mM EDTA, 0.6% SDS,
200 ng/ml proteinase K. RNAseA (Qiagen, Washington, DC,
USA) was added at a final concentration of 10 mg/ml and samples
were incubated at 37uC for 1 h followed by two rounds of phenol/
chloroform extractions. DNA was then precipitated by adding 2.5
volumes of EtOH and incubated at 280uC for 2 h. Samples were
centrifuged at 14000 rpm for 1 h, DNA pellets were washed in
70% EtOH and resuspended in water.
Real-time PCR analysis was performed on 100 ng of genomic
DNA using a set of primers/probe specific for the viral genome
and the Taqman universal PCR master mix (Applied Biosystems,
Foster City, CA, USA) [34]. Amplification was run on a 7900
Real-time PCR system (Applied Biosystems, Foster City, CA,
USA) with standard cycles. All the reactions were performed in
triplicate. Liver, spleen, kidney, muscle, heart and gonads were
colleted at P90 for rats injected at P30 and at P15, P30 and P90 for
rats injected at P4.
ELISA for the detection of anti-ARSB antibodies
The presence of circulating antibodies against the hARSB
protein in MPS VI rats was determined using a plate-binding
assay, as described previously [15]. Briefly, 96-well 200 microtiter
plates (Costar, Cambridge, UK) were coated with human ARSB
(Naglazyme - Galsulfase, BioMarin Europe Ltd., London, UK) in
100 ml of PBS overnight at 4uC. Plates were blocked for 2 h at
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with PBS containing 0.05% Tween 20 and incubated with 100 ul
of 1:50 dilutions of rat serum in PBS/Tween 0.05%/FBS 10% for
2 h at RT. The washing step was repeated once and 100 mlo f
biotinylated anti-rat IgG antibody (Vector Laboratories Ltd.,
Peterborough, UK) was added in PBS/Tween 0.05%/FBS 10%
for 1 h at RT. Binding was revealed by the addition of extravidin–
horseradish peroxidase (Sigma-Aldrich, Milan, Italy) followed by
o-phenylenediamine dihydrochloride (OPD) substrate (Sigma-
Aldrich, Milan, Italy). Absorbance at 450 nm (OD) was deter-
mined in an Infinite 200 microplate reader (Tecan, Mannedorf,
Switzerland). The OD observed in an assay represents a
qualitative measure of antibody affinity. As control we used sera
from normal and affected rats who did not receive the vector
(n=18); the average OD measured in control sera was considered
as the cut-off value for detection of anti-ARSB antibody presence.
Alcian-blue staining
7 mm paraffin sections from methacarn fixed livers were
rehydrated and stained with 1% Alcian blue (Sigma-Aldrich,
Milan, Italy) in hydrochloric acid. The counterstaining was
performed for 2 min with Nuclear-Fast red (Sigma-Aldrich,
Milan, Italy) and slides were mounted with Eukitt (Kaltek, Padua,
Italy).
ARSB activity assay and protein levels
Livers from injected and control rats were lysed in water by
freeze and thaw and protein concentration was determined using
the BCA protein assay reagent (Pierce Chemical Co, Boston, MA,
USA).
The ARSB assay was performed as described previously [15].
Briefly, 15–30 mg of protein or 20 ml of serum (diluted 1:2 with
water) were incubated with 40 ml of fluorogenic substrate, 4-
methylumbelliferyl-sulfate (12.5 mM Sigma-Aldrich, Milan, Italy),
for 3 h at 37uC in presence of 40 ml silver nitrate (0.75 mM, Carlo
Erba, Milan, Italy), both dissolved in NaOAc, 0.2 M, pH 5.6. The
reaction was stopped by adding 200 ml of the carbonate stop buffer
(0.5 M NaHCO3/0.5 M Na2CO3, pH 10.7), and the fluores-
cence of the 4-methylumbelliferone liberated was measured in an
Infinite 200 microplate reader (Tecan, Mannedorf, Switzerland)
using 365 nm excitation and 460 nm emission. The enzyme
activities were calculated using a standard curve of the fluorogenic
product, 4-methylumbelliferone (Sigma-Aldrich, Milan, Italy). For
tissue lysates and cells the activity is expressed as nmol/mg
protein/h. For serum samples, enzyme activity is calculated as %
of activity measured in serum from NR rats in each assay (reported
as 100%).
Cell culture conditions, transfection, AAV infection and
fluorescence detection
Primary human umbilical vein endothelial cells (HUVECs;
Promocell, Heidelberg, Germany) were cultivated according to the
manufacturer’s instructions.
HepG2 cells (ATCC-LGC Standards, Milan, Italy) were grown
in Dulbecco’s modified Eagle medium (DMEM, Celbio, Milan,
Italy) supplemented with 10% (w/v) FBS (GIBCO; Invitrogen
Corporation, Carlsbad, CA, USA), 4.5 g/l glucose, 2 mM
glutamine and penicillin (100 IU/ml)-streptomycin (10 mg/ml)
(Invitrogen Corporation, Carlsbad, CA, USA). All cells were
cultivated in a humidified incubator at 5% CO2 at 37uC.
The day before transfection HepG2 cells were plated in 6 well
plates (MW6) and transfected the day after with 2 mg of pAAV2.1-
TBG-eGFP or pAAV2.1-TBG-eGFP-WPRE-m using the Fugene
reagent (Roche, Basel, Switzerland). Fourty-eight hours after
transfection fluorescence intensity (OD) was measured in each well
with an Infinite 200 microplate reader (Tecan, Mannedorf,
Switzerland) using 485 nm excitation and 535 nm emission.
Pictures of each well containing eGFP-positive cells were taken
with a fluorescence microscope. All transfections were performed
in duplicate.
For transfection with ARSB expressing plasmids, HepG2 cells
were plated in MW6 and transfected with 1.5 ug of pAAV2.1-
TBG-felineARSB plasmids containing or not WPRE-m using
Fugene reagent (Roche). To normalize transfection efficacy, cells
in each well received 0.5 ug of pAAV2.1-CMV-eGFP plasmids.
48 h after transfection cells were incubated in serum free medium;
24 hours later eGFP fluorescence in each well was measured with
an Infinite 200 microplate reader (Tecan, Mannedorf, Switzer-
land); cells and media were then collected for analysis of ARSB
activity which was normalized on eGFP fluorescence intensity for
each sample by dividing the ARSB activity measured (nmol/mg/
h) for the eGFP fluorescence intensity (OD).
For infection with AAV vectors, HepG2 and HUVEC cells
were seeded 24 hrs prior to transduction. Cells were incubated
with the indicated vector preparation at a genomic particle per cell
ratio of 1610e5 and 5610e5, respectively. Cells were harvested
48 hrs post transduction by trypsin treatment. Transgene-
expressing cells were determined by flow cytometry using a BD
FACSCanto II (BD Biosciences, San Jose, CA). A minimum of
10000 cells was counted for each sample. The background
fluorescence level was set to 1%.
RNA extraction and RT-PCR for detection of eGFP
transcript
Liver, spleen and kidney of rats injected at P4 with AAV2/8-
TBG-eGFP vectors were collected at P15; total RNA was isolated
with TRIzol reagent (Invitrogen, Carlsbad, CA) as suggested by
the manufacturer and subjected to DNAse I (Invitrogen, Carlsbad,
CA) treatment to eliminate contaminant genomic DNA. cDNA
was synthesized from 1 mg of RNA using SuperScript III First-
Strand Synthesis System (Invitrogen, Carlsbad, CA) and then
subjected to RNAseH digestion (Invitrogen, Carlsbad, CA). RT-
PCR was performed on 1 ml of each cDNA with the following
primers: eGFP-Fw: 59-GACGGCAACTACAAGACC-39; eGFP-
Rev: 59-CTTGATGCCGTTCTTCTGC-39; Actin-Fw: 59-
GACCTCTATGCCAACACAG-39; Actin-Rev: 59 GAGCCAC-
CAATCCACACAG-39.
Statistical analyses
An unpaired t-test between the various data sets was performed
using the Microsoft Excel (Microsoft Corporation, Redmond, VA,
USA) t-test function. Significance at p#0.05 is indicated by a single
asterisk in the figures.
Supporting Information
Figure S1 Analysis of eGFP expression in livers of rats
injected with AAV2/8-TBG-eGFP and collected at P90. A)
Wild-type rats were injected at either postnatal day 4 (P4, upper
pictures), or at P30 (lower pictures) with 4610e13 gc/kg of AAV2/
8-TBG-eGFP. Animals were sacrificed at P90 and eGFP
expression was confirmed under a fluorescence microscope on
sections from transduced livers. Pictures from representative
animals in each group are shown. Magnification: 206. B) The
eGFP band intensity from Western blot analysis of livers from
animals in panel A and shown in Fig. 1B was reported on a linear
scale. The intensity of eGFP bands was quantified, normalized on
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compared to rats injected at P4 and sacrificed at P90. Results are
reported as mean 6 SE. The number of rats analyzed in each
group is reported in each bar.
(TIF)
Figure S2 Western Blot analysis of eGFP expression in
livers of rats injected with AAV2/8-TBG-eGFP. A, B, C)
Wild-type rats were injected at either postnatal day 4 (P4) or at
P30 with 4610e13 gc/kg of AAV2/8-TBG-eGFP. Animals
injected at P4 were sacrificed at P15, P30 or P90 (A and B),
while those injected at P30 were analysed both at P41 (C) and at
P90 (A and C). EGFP expression was compared among rats of the
different groups by Western blot analysis with anti-eGFP
antibodies. Protein loading was normalized by blotting with anti
Tubulin (a-Tub) antibodies. Time points of vector administration
and liver collection are reported in each picture. Representative
Western blots are shown for each animal group. D) Wild-type
(NR) and MPS VI (AF) rats were injected at P30 with 4610e13
gc/kg of AAV2/8-TBG-eGFP vectors. Animals were sacrificed at
P90 and eGFP expression was analyzed by Western blot analysis
with anti-eGFP antibodies. Protein loading was normalized by
blotting with anti Tubulin (a-Tub) antibodies. E) Wild-type rats
were injected at postnatal day (P)30 with 4610e13 gc/kg of
AAV2/8-TBG-eGFP or AAV2/8-TBG-eGFP-WPRE-m vectors.
Animals were sacrificed at P90 and eGFP expression was analyzed
by Western blot analysis with anti-eGFP antibodies. Protein
loading was normalized by blotting with anti Tubulin (a-Tub)
antibodies. Representative Western blots are shown from three
independent experiments. F) Wild-type rats were injected at
postnatal day (P)4 with 4610e13 gc/kg of either AAV2/8-TBG-
eGFP or AAV2/8-TBG-eGFP-miR142-Tx4 vectors. Animals
were sacrificed at P15 and eGFP expression in liver and spleen
was analyzed by Western blot with anti-eGFP antibodies. Protein
loading was normalized by blotting with anti Tubulin (a-Tub)
antibodies.
(TIF)
Figure S3 FACS analysis of eGFP-expressing human
hepatoma and endothelial cells after transduction with
AAV2/8. Human hepatoma (HepG2) and human umbilical vein
endothelial (HUVEC) cells were infected with 5610e5 gc/cell of
AAV2/8-TBG-eGFP (black bars) or AAV2/8-CBA-eGFP (white
bars) vectors. The percentage of eGFP expressing cells was
determined by FACS analysis. Results are reported as mean 6 SE
of three experiments.
(TIF)
Figure S4 RT-PCR analysis of eGFP expression in liver,
spleen and kidney of rats injected with AAV2/8-TBG-
eGFP. Wild-type rats were injected at postnatal day (P) 4 with
4610e13 gc/kg of AAV2/8-TBG-eGFP. Tissues were collected at
P15, RNA was isolated, retrotranscribed (RT+) and PCR-
amplified with eGFP- or Actin-specific primers. As control, non-
retrotranscribed RNA (RT2) was amplified for each sample in the
same conditions. Tissues from a non-injected rat (2) were used as
negative control.
(TIF)
Figure S5 Scatter plots of eGFP expression levels and
AAV vector genome copies from liver of rats injected
with AAV2/8-TBG-eGFP containing or not WPRE-m. The
eGFP Western blot band intensity normalyzed on tubulin (eGFP/
Tubulin, A) and AAV vector genome copies/molecule of diploid
genome (gc/mdg, B) from liver of animals shown in Fig. 4 were
represented as Scatter Plot. Mean 6 SE for each experimental
group is shown. *: p,0.05.
(TIF)
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